In the last three months, 7 analysts have published ratings on Guardant Health (NASDAQ:GH), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 1 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 2 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 0 | 0 |
| 3M Ago | 2 | 0 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $33.71, with a high estimate of $44.00 and a low estimate of $28.00. Highlighting a 10.7% decrease, the current average has fallen from the previous average price target of $37.75.
Decoding Analyst Ratings: A Detailed Look
The perception of Guardant Health by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Subbu Nambi | Guggenheim | Announces | Buy | $36.00 | - |
| Kyle Mikson | Canaccord Genuity | Raises | Buy | $38.00 | $30.00 |
| Tycho Peterson | Jefferies | Announces | Buy | $32.00 | - |
| Mason Carrico | Stephens & Co. | Maintains | Overweight | $44.00 | $44.00 |
| Kyle Mikson | Canaccord Genuity | Lowers | Buy | $30.00 | $45.00 |
| Alex Nowark | Craig-Hallum | Announces | Buy | $28.00 | - |
| Matthew Sykes | Goldman Sachs | Lowers | Buy | $28.00 | $32.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Guardant Health. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Guardant Health compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Guardant Health's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
To gain a panoramic view of Guardant Health's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Guardant Health analyst ratings.
Get to Know Guardant Health Better
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Guardant Health: A Financial Overview
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Guardant Health displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 30.9%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Guardant Health's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -68.24%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Guardant Health's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -101.32%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Guardant Health's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -6.59%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Guardant Health's debt-to-equity ratio surpasses industry norms, standing at 19.73. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
The Basics of Analyst Ratings
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.